Ethical challenges in paediatric clinical trials in multiple sclerosis

Therapeutic Advances in Neurological Disorders

Volumn 5, Issue 3, 2012, Pages 139-146

  Tenembaum, Silvia N ^a  

^a National Pediatric Hospital   (Argentina)

Author keywords

adolescence; childhood; clinical trials; ethics; immunomodulatory treatment; immunosuppression; multiple sclerosis; new therapies; recruitment

Indexed keywords

ALEMTUZUMAB; DACLIZUMAB; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; LAQUINIMOD; OCRELIZUMAB; OFATUMUMAB; PLACEBO; RITUXIMAB; TERIFLUNOMIDE;

ACUTE CELL LYSIS; ALOPECIA; ANGIONEUROTIC EDEMA; ARTHRALGIA; ATRIOVENTRICULAR BLOCK; AUTOIMMUNE HEPATITIS; BACKACHE; BRADYCARDIA; BREAST CARCINOMA; CHILL; CLINICAL TRIAL (TOPIC); CYTOKINE RELEASE SYNDROME; CYTOLYSIS; DIARRHEA; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DYSPNEA; FACIAL FLUSHING; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GOODPASTURE SYNDROME; GRAVES DISEASE; HERPES VIRUS INFECTION; HERPES ZOSTER; HOT FLUSH; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOMODULATION; INFECTION; INTERSTITIAL LUNG DISEASE; LIVER DYSFUNCTION; LIVER FAILURE; LIVER TOXICITY; LYMPHOCYTOPENIA; MEDICAL ETHICS; METASTASIS; MULTIPLE SCLEROSIS; OPPORTUNISTIC INFECTION; OVARY CANCER; PEDIATRIC CLINICAL TRIAL; PEDIATRICS; PERICARDIAL EFFUSION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RETINA MACULA EDEMA; REVIEW; RHABDOMYOLYSIS; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN CANCER; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TERATOGENICITY; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; VEIN THROMBOSIS; VITILIGO;

EID: 84860808732     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285612437360     Document Type: Review

References (34)

1. Altavilla A. Manfredi C. Baiardi P. Dehlinger-Kremer M. Galletti P. Alemany A. et al. (2012) Impact of the new European paediatric regulatory framework on ethics committees: overview and perspectives. Acta Paediatr 101: e27–e32.
2. Banwell B. Bar-Or A. Giovannoni G. Dale R.C. Tardieu M. (2011) Therapies for multiple sclerosis: considerations in the pediatric patient. Nat Rev Neurol 7: 109–122.
3. Beauchamp T.L. Childress J.F. (2009) Principles of Biomedical Ethics. Oxford: University Press.
4. Boiko A. Vorobeychik G. Paty D. Devonshire V. Sadovnick D. ; University of British Columbia MS Clinic Neurologists. (2002) Early onset multiple sclerosis: a longitudinal study. Neurology 59: 1006–1010.
5. Chitnis T. Glanz B. Jaffin S. Healy B. (2009) Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States. Mult Scler 15: 627–631.
6. Chitnis T. Tenembaum S. Banwell B. Krupp L. Pohl D. Rostasy K. et al.; for the International Pediatric Multiple Sclerosis Study Group. (2012) Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Mult Scler 18: 116–127.
7. Cohen J.A. Chun J. (2011) Mechanisms of fingolimod”s efficacy and adverse effects in multiple sclerosis. Ann Neurol 69: 759–777.
8. Coles A.J. Compston D.A. Selmaj K.W. Lake S.L. Moran S. Margolin D.H. et al. (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359: 1786–1801.
9. Cossburn M. Pace A.A. Jones J. Ali R. Ingram G. Baker K. (2011) Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 77: 573–579.
10. Duquette P. Murray T.J. Pleines J. Ebers G.C. Sadovnick D. Weldon P. et al. (1987) Multiple sclerosis in childhood: clinical profile in 125 patients. J Pediatr 111: 359–363.
11. European Union. (2008) Ethical considerations for clinical trials on medicinal products conducted with the paediatric population. Eur J Health Law 15: 223–250.
12. Fromont A. Binquet C. Sauleau E.A. Fournel I. Bellisario A. Adnet J. et al. (2010) Geographic variations of multiple sclerosis in France. Brain 133 1889–1899.
13. Ghezzi A. (2010) Therapeutic strategies in childhood multiple sclerosis. Ther Adv Neurol Disord 3: 217–228.
14. Ghezzi A. Amato M.P. Annovazzi P. Capobianco M. Gallo P. La Mantia L. et al. (2009) Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. Neurol Sci 30: 193–199.
15. Ghezzi A. Deplano V. Faroni J. Grasso M.G. Liguori M. Marrosu G. et al. (1997) Multiple sclerosis in childhood: clinical features of 149 cases. Mult Scler 3: 43–46.
16. Gill D. (2004) Ethical principles and operational guidelines for good clinical practice in paediatric research. Recommendations of the ethics working group of Confederation of European Specialists in Paediatrics (CESP). Eur J Pediatr 163: 53–57.
17. Hauser S.L. Waubant E. Arnold D.L. Vollmer T. Antel J. Fox R.J. et al. (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.N Engl J Med 358: 676–688.
18. Henschel A.D. Rothenberger L.G. Boos J. (2010) Randomized clinical trials in children – ethical and methodological issues. Curr Pharm Des 16: 2407–2415.
19. Kappos L. Li D. Calabresi P.A. O'Connor P. Bar-Or A. Barkhof F. et al. (2011) Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 378: 1779–1787.
20. Khatri B. Barkhof F. Comi G. Hartung H.P. Kappos L. Montalban X. et al. (2011) Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomized extension of the TRANSFORMS study. Lancet Neurol 10: 520–529.
21. Killestein J. Rudick R.A. Polman C.H. (2011) Oral treatment for multiple sclerosis. Lancet Neurol 10: 1026–1034.
22. Klein N.P. Ray P. Carpenter D. Hansen J. Lewis E. Fireman B. et al. (2010) Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies. Vaccine 28: 1062–1068.
23. Knellwolf A.L. Bauzon S. Alberighi O.D. Lutsar I. Bácsy E. Alfarez D. et al. (2011) Framework conditions facilitating paediatric clinical research. Ital J Pediatr 37: 12.
24. Kuntz N.L. Chabas D. Weinstock-Guttman B. Chitnis T. Yeh E.A. Krupp L. et al. (2010) Treatment of multiple sclerosis in children and adolescents. Expert Opin Pharmacother 11: 505–520.
25. Naismith R.T. Piccio L. Lyons J.A. Lauber J. Tutlam N.T. Parks B.J. et al. (2010) Rituximab add-on therapy for breakthrough relapsing multiple sclerosis. A 52-week phase II trial. Neurology 74: 1860–1867.
26. Polman C.H. Reingold S.C. Barkhof F. Calabresi P.A. Clanet M. Cohen J.A. et al. (2008) Ethics of placebo-controlled clinical trials in multiple sclerosis. A reassessment. Neurology 70: 1134–1140.
27. Polman C.H. Reingold S.C. Barkhof F. Calabresi P.A. Clanet M. Cohen J.A. et al. (2008) Ethics of placebo-controlled clinical trials in multiple sclerosis. Appendix e-3. Example of sample size calculation for placebo versus active-arm comparator trials. Neurology 70: 1–2.
28. Renoux C. Vukusic S. Mikaeloff Y. Edan G. Clanet M. Dubois B. et al. (2007) Natural history of multiple sclerosis with childhood onset. N Engl J Med 356: 2603–2613.
29. Taylor P.C. Quattrocchi E. Mallett S. Kurrasch R. Petersen J. Chang D.J. (2011) Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naïve, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis 70: 2119–2125.
30. Tenembaum S.N. (2010) Therapy of multiple sclerosis in children and adolescents. Clin Neurol Neurosurg 112: 633–640.
31. US Department of Health, Education, and Welfare. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. (1979) The Belmont Report. Ethical Principles and Guidelines for the Protection of Human Subjects of Research. http://ohsr.od.nih.gov/guidelines/belmont.html
32. World Medical Association. (2008) Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects; 59th WMA General Assembly, Seoul. http://www.wma.net/en/30publications/10policies/b3/index.html
33. Wynn D. Kaufman M. Montalban X. Vollmer T. Simon J. Elkins J. et al. (2010) Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 9: 381–390.
34. Yeh E.A. Waubant E. Krupp L.B. Ness J. Chitnis T. Kuntz N. et al. (2011) Multiple sclerosis therapy in pediatric patients with refractory multiple sclerosis. Arch Neurol 68: 437–444.